New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer
A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.
